Key Takeaways
• Tirzepatide is marketed under different brand names depending on its approved use, with Mounjaro commonly prescribed for type 2 diabetes and Zepbound used for chronic weight management.
• Although the names differ, both medications contain the same active ingredient and work through the same dual-action mechanism targeting GLP-1 and GIP receptors.
• Brand availability can vary by country and approval status, but dosing is generally similar, with tirzepatide given as a once-weekly injection.
Overview
When reviewing tirzepatide brand names, we often encounter a variety of labels tied to geography, indication, and regulatory status. From the US to Europe, Asia to the UK, each market treats this dual-agonist therapy slightly differently. In this guide, we’ll walk through global brand names, approvals, study formulations, generics status, marketing nuances, and dosing details to help you navigate the landscape.
A quick note: the drug’s dual action on GLP-1 and GIP receptors has set it apart from single-agonist drugs. That means brand names for the same active ingredient can signal different approved uses or dosage options. We’ll link you to deeper dives as we go, so you can learn more about tirzepatide for type 2 diabetes or tirzepatide for weight loss depending on what you’re exploring.
Let’s start with a regional breakdown of every brand name around the world.
All brand names globally
Tirzepatide’s global footprint spans multiple continents, each with its own naming conventions and approved uses. Below is a summary of the primary brand names by region and their indications.
| Region | Brand name | Approved indications |
|---|---|---|
| United States | Mounjaro; Zepbound | Type 2 diabetes; Obesity (weight loss); Moderate to severe OSA |
| European Union | Mounjaro | Type 2 diabetes |
| United Kingdom | Mounjaro | Type 2 diabetes; Weight management |
| Japan | RevoNate | Type 2 diabetes |
In the United States, it is available as Mounjaro for type 2 diabetes and Zepbound for obesity and sleep apnea (Drugs.com).
The European Union approved Mounjaro for type 2 diabetes in September 2022, while the UK MHRA expanded its label to include weight management in November 2023 (Wikipedia).
Japan’s Ministry of Health markets tirzepatide under the name RevoNate, reflecting local branding preferences (Alpha Male Clinic).
Mounjaro: what it’s approved for
Mounjaro, Eli Lilly’s proprietary name for tirzepatide in diabetes, is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The FDA originally green-lit Mounjaro in May 2022, and by mid-2025, expanded its approval to include adolescents aged 10 years and older with type 2 diabetes (Lilly). In the European Union, Mounjaro has carried a type 2 diabetes indication since September 2022 (Wikipedia).
As a dual GIP and GLP-1 receptor agonist, Mounjaro offers robust HbA1c reductions and weight benefits beyond traditional GLP-1 therapies, which positions it strongly in guidelines.
Zepbound for weight loss
Zepbound represents tirzepatide’s dedicated mantle in weight management, earning FDA approval in November 2023 for chronic weight loss in adults with obesity or overweight plus at least one weight-related comorbidity. In the SURMOUNT-1 trial, participants without diabetes achieved an average 18% body weight reduction at the highest (15 mg) dose (UCHealth Today). That remarkable outcome underpinned Zepbound’s rapid uptake in obesity clinics.
Later, FDA fast track, priority review, and breakthrough therapy designations highlighted Zepbound’s efficacy in moderate to severe obstructive sleep apnea, approved in December 2024 (Wikipedia). Clinicians now recognize its airway and metabolic benefits as complementary to weight management strategies.
Research formulations and study names
Tirzepatide’s clinical backbone rests on robust Phase 3 programs spanning diabetes and obesity. In the diabetes realm, the SURPASS series – from SURPASS-1 through SURPASS-5 – evaluated doses from 2.5 mg to 15 mg once weekly, often compared head-to-head with active treatments like semaglutide in SURPASS-2 (tirzepatide vs semaglutide). Trials such as SURPASS-3 and SURPASS-4 expanded into combination therapy with basal insulin, while SURPASS-Japan confirmed local efficacy.
For weight management, the SURMOUNT trials led the charge – SURMOUNT-1 showcased primary weight loss efficacy, SURMOUNT-2 focused on overweight individuals with type 2 diabetes, and SURMOUNT-3 explored long-term maintenance. Each study reinforced this med’s versatility across metabolic indications. Across these trials, formulations remained consistent: a once-weekly, prefilled pen delivering 2.5 mg to 15 mg doses.
Beyond SURPASS and SURMOUNT, early-phase research tested tirzepatide combinations with other agents, but it’s these flagship studies that inform our brand naming and dosing conventions.
Tirzepatide generics status
At present, there are no FDA-approved generic versions of tirzepatide, as patent protections extend into the mid-2030s. That exclusivity keeps originator brands at the forefront of prescriber and patient choices. Post-May 2025, the FDA restricted compounding of tirzepatide as an exact generic copy, limiting pharmacies to custom doses or alternative formulations only under specific medical necessity.
Nevertheless, compounded tirzepatide remains an option for some, with clinics such as Shed, Peak Wellness, MEDVi, and Henry Meds offering injectable and even experimental oral tablets at lower price points. Quality and dosing consistency can vary, so we encourage clinicians to weigh risks carefully.
Until true generics emerge, brand and compounding avenues constitute the main paths for accessing tirzepatide therapy.
Marketing differences by brand
Mounjaro and Zepbound don’t just share an active ingredient – they occupy distinct marketing lanes. Mounjaro’s narrative centers on its pioneering dual-agonist role for type 2 diabetes, with messaging geared toward endocrinologists and primary care physicians. Zepbound campaigns highlight dramatic weight loss and metabolic benefits, often targeting obesity specialists and direct-to-consumer channels.
Mounjaro’s price ranges from roughly $349 to $1,399 per month, depending on provider discounts and insurance coverage (NutritionNC). Zepbound’s list price exceeds $1,000 monthly with varying payer uptake.
Sales figures underscore this dichotomy – combining Mounjaro and Zepbound, Eli Lilly pulled in $10.1 billion in Q3 2025, outpacing Keytruda and boosting full-year guidance to over $63 billion (STAT News).
Brand-specific dosing instructions
Though Mounjaro and Zepbound share a delivery system – a once-weekly, prefilled pen – they differ in dose strength and titration schedules. Mounjaro comes in six increments (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), allowing stepwise escalation every four weeks to optimize glycemic control and tolerability as of 2025. Zepbound uses three doses (5 mg, 10 mg, 15 mg) with typical titration starting at 5 mg weekly and increasing in four-week intervals based on weight-loss response.
We generally recommend beginning Mounjaro at 2.5 mg weekly for the first month, then progressing through higher strengths until reaching a maintenance dose – often 10 mg or 15 mg. For weight management, initiating Zepbound at 5 mg weekly before stepping up to 10 mg and 15 mg allows tolerance monitoring and dose optimization as outlined in tirzepatide for weight loss.
Always refer to each brand’s prescribing information and patient support resources when designing a dosing plan.
FAQ
The most widely recognized brand name is Mounjaro, especially in diabetes treatment, while Zepbound is increasingly known for weight loss treatment.
No, both contain tirzepatide as the active ingredient. The main difference is the approved indication and how each product is marketed.
Yes, medication branding and approvals often vary between countries, so tirzepatide may be introduced under different names depending on local regulations.